SonoSemi Medical Completes Hundreds of Millions RMB B+ Financing to Accelerate Global Expansion of Intelligent Pan-Vascular Interventional Solutions

Recently, VCBeat learned thatPan-vascular active interventional device company Sonosemi Medical Co., Ltd. (hereinafter referred to as “Sonosemi”) announced the completion of its Series B+ financing round, amounting to hundreds of millions of yuan.。

This round is presented byAlwin Investment, FIL CapitalCo-led the investment round,Furong InvestmentExisting shareholders will continue to make follow-on investments. The funds will be primarily allocated to the R&D and regulatory registration of core product pipelines, the establishment of supply chain and commercialization channels, as well as clinical and academic promotion, thereby continuously strengthening SONOSEMI’s platform-based leading advantage in the field of pan-vascular active interventional medicine.

SONOSEMI, founded in 2020 and headquartered in Shenzhen, is a national high-tech enterprise and a nationally recognized “Little Giant” enterprise specializing in specialized, refined, distinctive, and innovative technologies. Focusing on cardiovascular and cerebrovascular diseases—including coronary artery disease, peripheral vascular disease, structural heart disease, heart failure, and intracranial vascular and neurological disorders—the company has built a full-chain innovation ecosystem engine. By maintaining technological innovation as a practitioner of therapeutic advancements in cardiovascular and cerebrovascular care, SONOSEMI is committed to providing physicians and patients with more intelligent diagnostic and therapeutic products.

Since its inception, SONOSEMI has formulated a product pipeline strategy dedicated to deepening its presence in the arterial calcification sector and reshaping a new paradigm for green, precise, and safe diagnosis and treatment. Leveraging shockwave and ultrasound technology platforms as strategic pillars, the company is driving innovation in the coronary PCI sector, actively building an intelligent diagnostic and therapeutic product matrix, and gradually expanding into clinical scenarios involving intracranial and peripheral vascular calcified lesions, thereby replicating this new paradigm for the treatment of calcified lesions.

SONOSEMI: A Collection of Products Approved in 2026

Since its previous funding round in 2023, SONOSEMI has achieved a comprehensive transition—from validating technical principles and securing approval for its first product to obtaining five Class III medical device certifications and scaling up commercialization. The closing of this Series B+ financing round marks a shift in the capital market’s valuation of SONOSEMI, moving from early-stage recognition of its technological potential to a deep endorsement of its commercial execution capabilities and long-term growth certainty.

Leveraging its dual-engine platform of “therapy + imaging,” SONOSEMI’s product pipeline demonstrates exceptional innovation and industry leadership, with approximately 20 core products currently under development. To date, the company has secured five Class III medical device registration certificates from the National Medical Products Administration (NMPA), filed 168 patent applications, and obtained 92 granted patents. Complemented by dozens of integrated circuit layout designs and software copyrights, this establishes a comprehensive intellectual property protection system covering core components, complete equipment, and software systems.

Behind the rapid expansion of its product portfolio lies the support of an integrated R&D, production, and sales platform, along with a robust quality system. Currently, the company’s standardized production lines and quality management system have obtained international certifications including ISO 13485, MDSAP, QSD, and KGMP. Its core team comprises multidisciplinary talents from fields such as semiconductors, precision instruments, clinical practice, and regulatory affairs, possessing end-to-end engineering capabilities ranging from underlying chip design and independent catheter development to registration and mass production. This provides a solid foundation for the continuous iteration and commercialization of multiple product pipelines.

Product Side, CompanyChina's First Independently Developed Intracoronary Shockwave Therapy System (Device: ISL100 Pro, Catheter: LiqMagic C14)Approved by the NMPA for market launch in October 2023, becomingThe First Domestically Produced Product in China to Achieve Localization of Intravascular Lithotripsy (IVL) Technology, breaking the monopoly of US-based Shockwave Medical in the field of coronary artery calcification treatment.

Coronary IVL Products

Leveraging its proprietary magnetically isolated pulsed power supply and multi-channel independent electrical drive technology, the product can effectively and safely fracture deep calcified plaques within the vessel wall while fully preserving the vascular intima. It precisely addresses the challenge of treating severe calcified lesions that are difficult to manage with conventional percutaneous coronary intervention (PCI). Clinical research findings on this product have been published in prestigious international journals, with all 11 core technical indicators reaching internationally leading levels.

With this as the core pivot, the company continuously refines its comprehensive solutions for calcified lesions, ranking among the first tier of domestic manufacturers.Peripheral Arterial Shockwave SystemSuccessfully approved; capable of efficiently treating long-segment, multi-segment peripheral vascular calcified lesions;Newly Launched in 2026Coronary Scoring Balloon, further enriching the product portfolio for the diagnosis and treatment of complex coronary artery lesions.

In addition, leveraging its self-developed micro phased-array transducer technology, SONOSEMI is simultaneously advancingIntracardiac Echocardiography (ICE) and Intravascular Ultrasound (IVUS) ProductsCommercialization achieved. The ICE system gained approval through an innovative green channel, with core components achieving 100% domestic production; the IVUS product received NMPA approval in late 2025, continuously reducing reliance on imports.

Shockwave therapy addresses “how to treat,” while ultrasound answers “how to visualize.” The integration of both technologies within the clinical pathway enables SONOSEMI to progressively build an interventional diagnosis and treatment system covering the entire process—from preoperative assessment and intraoperative guidance to postoperative verification—constituting its true competitive moat that distinguishes it from single-device manufacturers.

Leveraging the synergistic advantages of its dual-platform technology combining shockwave and ultrasound, SONOSEMI continues to expand the clinical application boundaries of its products and deepen its multi-departmental diagnostic and therapeutic layout. Vertically, it is deeply engaged in complex coronary artery disease scenarios, including coronary calcification, chronic total occlusion (CTO) lesions, and in-stent restenosis (ISR). Horizontally, it has completed its expansion from cardiology to vascular surgery and is proactively entering the neurology sector, continuously exploring innovative diagnostic and therapeutic solutions that integrate both technologies to solidify its long-term competitive edge in product innovation.

Following the completion of technical validation, SONOSEMI has continued to accelerate its commercialization process, achieving simultaneous breakthroughs in both domestic and international markets.

In the Chinese market, the core product, the coronary intravascular lithotripsy (IVL) system, has been adopted by hundreds of hospitals nationwide, with over 90% being Grade 3A hospitals. It comprehensively covers major cardiovascular diagnosis and treatment centers across China, pioneering the large-scale hospital adoption and volume growth of domestically produced coronary IVL systems.

Global expansion is accelerating in tandem, with the company initially focusing on markets along the “Belt and Road” initiative; its overseas distribution network now covers more than 25 countries and regions. Notably, its coronary intravascular lithotripsy (IVL) products successfully obtained official regulatory approvals in Indonesia and Malaysia in 2025, making them among the first Chinese-made coronary IVL products to enter mainstream Southeast Asian markets.

Leveraging its achievements in technological innovation and large-scale implementation, the company has continued to gain recognition from both the industry and policy sectors, with its industry credibility and brand influence steadily rising.

At the corporate level, the company has been recognized as a National-Level “Little Giant” in Specialized, Refined, Distinctive, and Innovative (SRDI) Enterprises, a National High-Tech Enterprise, and a Potential Unicorn of Shenzhen. It won the Second Prize (ranking first nationwide) in the Corporate Category of the “Maker China” Medical Equipment Competition, and was included in VCBeat’s 2026 Future Healthcare 100 list and the 2025 Innovation Index for the Pan-Vascular Field in the Medical Device Industry (top 10 companies), demonstrating its comprehensive strength in technological innovation and engineering capabilities.

At the product level, SONOSEMI’s intravascular shockwave device won the 2025 German Red Dot Design Award and the Global Cardiovascular Technology Innovation Award. Its coronary shockwave therapy system and intracardiac echocardiography (ICE) imaging system were also selected for provincial and national innovative product catalogs, reflecting dual recognition of the products in terms of design innovation and clinical value.

From 0 to 1 technological breakthrough, from 1 to 10 commercial validation, SONOSEMI has completed a key leap in six years. InLiu Bin, Founder and CEO of SONOSEMIIt appears that this round of financing marks another significant milestone in the company’s journey to deepen its expertise in the active interventional pan-vascular sector. At this critical juncture, as core products sequentially obtain regulatory approvals and global commercialization is fully rolled out, the capital infusion will accelerate the company’s transition from single-region commercial implementation to large-scale global development.

“Since its inception, SONOSEMI has remained committed to centering on clinical needs and grounding its development in foundational technological innovation,” stated Liu Bin. From the very beginning, the company has dedicated itself to breaking the monopoly of overseas technologies and building a comprehensive product portfolio for domestically produced active interventional diagnosis and treatment. Looking ahead, SONOSEMI Medical will continue to collaborate with industry partners to strengthen its technological barriers, accelerate the translation of innovative achievements into practical applications, and ensure that more precise and safer interventional diagnostic and therapeutic solutions benefit patients and healthcare providers worldwide, steadily advancing toward its vision of becoming an internationally leading high-end medical device enterprise.

Alwin Investmentstated: “As a professional investment institution with a long-term focus on the life sciences and innovative healthcare sectors, we believe that SONOSEMI’s focus on active pan-vascular interventional solutions addresses genuine, urgent, and underserved needs in clinical diagnosis and treatment, offering significant patient benefits alongside clear commercialization prospects. The SONOSEMI team combines robust engineering R&D capabilities with strong clinical translation expertise, and multiple core products have already demonstrated their value and commercial potential in real-world applications. We are optimistic about the company’s continued accumulation of strengths in its technology platform, product pipeline, and commercial execution, and we believe SONOSEMI will grow into a benchmark enterprise in China’s pan-vascular interventional field.”

FIL Capital“As one of the earliest institutional investors in SONOSEMI, we firmly believe in the long-term growth potential and global market opportunities of the active pan-vascular intervention sector, as well as SONOSEMI’s foundational technological expertise and platform capabilities in shockwave therapy and intravascular ultrasound. We have consistently made significant additional investments during the company’s subsequent development phases. SONOSEMI’s commitment to innovation and efficient execution has further solidified its business foundation and established a leading market position. FIL Capital looks forward to working closely with the company and both existing and new shareholders to jointly promote the innovative development of active pan-vascular interventional devices worldwide.”

Furong Investmentstated: “Furong continues to leverage Fudan University’s research commercialization platform to provide sustained support for SONOSEMI’s Series B+ development. The company boasts prominent proprietary technologies and a mature industry-academia-research collaboration model, with multiple products breaking through overseas technological blockades and aligning with the national strategy for domestic substitution. We will continue to integrate clinical, scientific research, and industrial incubation resources from universities to help enterprises connect with cutting-edge scientific achievements, thereby accelerating the translation of technological innovation into clinical value.”

Alwin Capital is a specialized investment fund focused on the frontier of life sciences. Its founding team has been deeply rooted in China’s pharmaceutical industry for two decades, combining industrial and financial expertise with extensive experience in investment research. In recent years, leveraging professional research, scientific thematic insights, a robust investment research framework, and mature portfolio management, Alwin Capital has systematically positioned itself in the cutting-edge areas of life sciences in China. It has nurtured several leading companies in fields such as gene editing, nucleic acid therapeutics, cell therapy, and molecular diagnostics. Additionally, with keen investment judgment, it has successfully invested in multiple star projects at the intersection of innovative technology and life sciences.

Eight Roads Ventures is a global venture capital firm focused on investing in early-stage and growth-stage companies in the healthcare and technology sectors. Currently, Eight Roads Ventures manages over $11 billion in assets worldwide, with investment teams located in China, India, Japan, Europe, and the United States, having invested in more than 350 high-growth innovative enterprises. With over 25 years of venture capital experience in Greater China, Eight Roads Ventures has invested in industry-leading companies such as Alibaba, WuXi AppTec, GuShenTang, Aier Eye Hospital, and Insilico Medicine.

Furong Investment, established in 2014 and originating from Fudan University, focuses on early-stage investment and incubation in the fields of artificial intelligence and semiconductors, new energy and advanced materials, biopharmaceuticals, and future industries. Committed to building a full-chain empowerment ecosystem from proof-of-concept to industrialization, it has become a technology transfer platform that “best understands scientists.”